Yarrow Bioscience
YARW
38 hedge funds and large institutions have $579M invested in Yarrow Bioscience in 2018 Q1 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
70.3% more ownership
Funds ownership: 0% → 70.3% (+70%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$135M |
| 2 |
Janus Henderson Group
London,
|
+$69.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$54M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
+$49.4M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$46M |
Top Sellers
YARW Hedge Fund Activity: Q1 2018 in Review
38 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q1 2018, worth a combined $579M.
Buyers outnumbered sellers: 38 funds opened new YARW positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $135M.
- 38 institutional investors held Yarrow Bioscience (YARW) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $579M of Yarrow Bioscience stock for Q1 2018.
- 38 funds opened new Yarrow Bioscience positions in Q1 2018 and 0 closed out, a net change of +38 holders.
- The largest Yarrow Bioscience buyer in Q1 2018 was Vivo Capital, an estimated $135M added.
Based on aggregated 13F filings for Q1 2018.